Catalent to Partner with Cybin for Fast-Dissolve Formulation of Psychiatric Disorders Treatment
March 22nd 2021Cybin will use Catalent’s Zydis orally disintegrating tablet technology for the delivery of its novel deuterated tryptamine, CYB003, a potential therapy for treatment-resistant psychiatric disorders.
Aceto Expands Biopharmaceutical and Cell Culture Reagent Portfolio to Meet Customer Demand
March 18th 2021Using the capabilities of Pharma Waldhof, one of Aceto’s facilities in Düsseldorf, Germany, the company plans to provide customers with access to raw materials, tested products for pharmaceutical cell culture applications, and cell culture media ingredients.
Catalent to Increase Manufacturing Capacity at Italian Facility for J&J COVID-19 Vaccine
March 18th 2021Under an expanded agreement with J&J, Catalent Biologics will increase manufacturing capacity at its Anagni, Italy, site to accommodate the large-scale commercial supply of Janssen’s COVID-19 vaccine.
Gilead and Merck to Collaborate on Long-Acting HIV Treatment
March 16th 2021The companies will combine combining Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen aimed at treating HIV.
Sagent Pharmaceuticals Issues Voluntary Nationwide Recall for its Low Blood Pressure Treatment
March 15th 2021Sagent Pharmaceuticals is voluntarily recalling three lots of Phenylephrine Hydrochloride Injection, USP (10 mg/mL) to the user level because of a customer complaint regarding potentially loose crimped vial overseals, which can result in a non-sterile product.